OncoMatch/Clinical Trials/NCT06435910

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Is NCT06435910 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DC vaccines for multiple myeloma or plasmacytoma.

Phase 1RecruitingShenzhen Geno-Immune Medical InstituteNCT06435910Data as of May 2026

Treatment: DC vaccines — The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Prior therapy

Must have received: combination therapies

Very good partial or complete remission (CR) after prior combination therapies.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify